Clear Street raised the firm’s price target on Structure Therapeutics (GPCR) to $99 from $61 and keeps a Buy rating on the shares. The Phase 2b Access 36-week data underscore aleniglipron’s ...
H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60 and keeps a Buy rating on the shares. The firm says its key opinion leader feedback ...
Investing.com - Stifel has raised its price target on Structure Therapeutics (NASDAQ:GPCR) to $90.00 from $50.00 while maintaining a Buy rating on the stock. The new target represents nearly 30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback